• 1
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463472.MEDLINE
  • 2
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling M-H, et al. Impact of pegylated interferon alfa 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:13031313.MEDLINE
  • 3
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339:14851492.MEDLINE
  • 4
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffmann M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958965.MEDLINE
  • 5
    Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975982.MEDLINE
  • 6
    Heathcote EJ, Shiffmann ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L, Reindollar R, et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:16731680.MEDLINE
  • 7
    Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, Ramadori G, et al. Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [Abstract]. J Hepatol 2002; 36(suppl 1):3.
  • 8
    Shiffman ML. Hepatitis C and co-morbid conditions. AASLD Single Topic Conference, Chicago, IL, April, 2002.
  • 9
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823830.MEDLINE
  • 10
    Everson GT, Trouillot T, Trotter J, Skilbred J, Halprin A, McKinley C, Fey B, et al. Treatment of decompensated cirrhotics with a slow-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy. Hepatology 2000; 32: 308A (abstract).
  • 11
    Crippin JS, Sheiner P, Terrault NA, McCashland T, Charlton M. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 2002; 8:350355.MEDLINE
  • 12
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver, transplant recipients. Hepatology 2002; 36:202210.MEDLINE
  • 13
    Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32:852858.MEDLINE
  • 14
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32:673684.MEDLINE
  • 15
    Bizollon T, Palazzo U, Ducerf C, Chevalier M, Eliott M, Baulieux J, Pouyet M, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500504.MEDLINE
  • 16
    Shakil AO, McGuire B, Crippin JS, Conjeevaram HS, Teperman L, Gish RG, Kwo P, et al. Interferon-alfa 2b and ribavirin combination therapy in liver transplant recipients with recurrent hepatitis C. Hepatology 2000; 32: 216A (abstract).